公司动态 - 公司将于2025年8月14日美国东部时间下午5点举行2025年第二季度企业更新电话会议 [1] - 电话会议可通过拨打800-717-1738接入 需要求接入Precipio电话会议 [1] - 听众可提前将问题发送至investors@precipiodxcom 管理层将在电话会议中尽力解答 [2] - 电话会议录音将在约24小时后通过公司官网投资者页面提供 [2] 公司业务 - 公司是一家专注于癌症诊断的医疗生物技术企业 致力于解决癌症误诊问题 [3] - 通过开发诊断产品和服务 提供更高准确性 改进实验室工作流程 最终改善患者治疗效果并降低医疗费用 [3] - 公司在实验室中设计 测试 验证并临床使用创新技术 改善诊断结果 [3] - 公司将技术商业化作为专有产品 服务全球实验室社区 扩大影响力以消除误诊 [3] 投资者关系 - 更多信息可通过公司官网https://wwwprecipiodxcom获取 [4] - 公司在X平台(原Twitter) LinkedIn和Facebook上设有官方账号 [4] - 公司通过官网和社交媒体与投资者及公众沟通 包括公司披露 投资者演示文稿 SEC文件等 [4] - 官网和社交媒体发布的信息可能被视为重大信息 建议定期查看 [4] 联系方式 - 投资者咨询邮箱investors@precipiodxcom [6] - 投资者咨询电话+1-203-787-7888转523 [6]

BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 21,562,500 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 2,812,500 additional shares, at the public offering price of $3.20 per share. The aggregate gross proce ...

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ps ...

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/capricor-therape ...

WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. T ...

RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Partici ...

文章核心观点 PolTREG及其美国子公司Immuthera获得美国FDA积极意见 为1型糖尿病前期注册试验铺平道路 若成功 PTG - 007将成全球首个在此阶段注册的疗法 公司后续计划向FDA提交正式IND会议申请 [2][3] 公司进展 - 公司宣布FDA发布正式会议协议 确认临床数据足以支持IND申请 并列出加速美国开发的监管途径 [2] - 公司将在IND申请中申请快速通道 突破性疗法或再生医学先进疗法指定 [4] - 公司计划在未来几周向FDA提交正式IND会议申请 [6] 合作与支持 - 年中公司成立100%控股的美国子公司Immuthera [9] - 七月糖尿病和神经免疫学专家加入公司科学顾问委员会 [9] - 年初Noble Capital Markets和Kinexum Services支持公司美国注册工作 [9] - 公司与Antion Biosciences合作开发下一代同种异体TREG疗法 [9] 产品信息 - 公司领先产品PTG - 007为早期1型糖尿病自体Treg疗法 准备进行2/3期临床试验 公司正寻求合作 [6] - 公司开发多编辑和同种异体CAR - Treg细胞疗法 结合PTG - 007为各阶段1型糖尿病患者提供临床解决方案 [9] FDA协议要点 - FDA认为公司3期1型糖尿病临床数据足以支持PTG - 007在1、2期无症状患者适应性2/3期研究的直接获益前景 [4] - FDA接受在试验统计分析中纳入波兰1期患者 [4][9] - FDA可能将适应性2/3期研究视为注册试验 加速PTG - 007在美国的批准 [4][9] - FDA认为总体研究设计合理 治疗潜在益处大于风险 确认临床数据足以支持美国研究的IND申请 [5] - FDA希望IND申请中包含技术转让至美国的数据 [9] 公司介绍 - 公司是基于T调节细胞开发自身免疫疗法的全球领导者 拥有包括多种细胞疗法的强大平台 [6] - 子公司Immuthera在美国和加拿大开拓基于细胞的疗法临床开发 可利用公司研发能力和资产管线 正寻求投资 [7]

Key Takeaways BCRX is set to report Q2 earnings on Aug. 4, with consensus estimates of $148.85M in sales and $0.03 EPS.Orladeyo sales likely rose on strong prescription trends; label expansion for children under FDA review.SG&A costs expected to rise on global launch activities, while R&D spend declines from pipeline restructuring.BioCryst Pharmaceuticals (BCRX) is slated to report its second-quarter 2025 results on Aug. 4, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the ...

For the quarter ended June 2025, Alnylam Pharmaceuticals (ALNY) reported revenue of $773.69 million, up 17.3% over the same period last year. EPS came in at $0.32, compared to $0.56 in the year-ago quarter.The reported revenue represents a surprise of +14.96% over the Zacks Consensus Estimate of $673 million. With the consensus EPS estimate being -$0.03, the EPS surprise was +1166.67%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

根据提供的文档内容，未包含具体的公司或行业分析信息，主要涉及分析师披露和免责声明等内容。因此，按照任务要求，跳过不相关的部分，不进行总结输出。 当前文档无实质性行业或公司研究内容可供提取关键要点 [1][2][3]